Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $78.23 and traded as high as $90.80. Kiniksa Pharmaceuticals International shares last traded at $89.20, with a volume of 2,320,220 shares trading hands.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Results surpassed estimates: Third-quarter EPS was $0.56, up from $0.23 a year earlier and above consensus estimates of approximately $0.32–$0.37. Revenue reached $285.97 million, exceeding the roughly $260.66 million analyst forecast. Kiniksa Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: ARCALYST continues to drive growth: The cardiovascular drug generated approximately $286 million in third-quarter net product revenue, representing about 58% year-over-year growth. Penetration among patients with multiple recurrences reached 23%, indicating continued room for expansion. Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Guidance was raised: Kiniksa now expects 2026 ARCALYST net product revenue of $1.045 billion to $1.050 billion, reinforcing expectations for sustained commercial momentum. Kiniksa Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Pipeline milestone: KPL-387 pivotal Phase 3 data is expected in the second half of 2027. The program could broaden Kiniksa’s portfolio, but the catalyst remains relatively distant and carries clinical-development risk. Kiniksa Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Reported short interest was zero shares as of October 26, offering no indication of meaningful short-selling pressure, although the figure may reflect reporting or data limitations.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on KNSA shares. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.14.

Kiniksa Pharmaceuticals International Price Performance

The firm has a 50-day simple moving average of $78.23 and a 200-day simple moving average of $59.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Insider Activity

In related news, CAO Michael Megna sold 4,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP raised its position in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after acquiring an additional 134 shares during the period. Curry Webb Wealth Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth $29,000. KBC Group NV purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $34,000. Nykredit A S bought a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at $34,000. Finally, USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $69,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.